Moderna closed +176.97% and extended to +212% AH on the first mRNA cancer prevention Phase 3 win. SPCX unlocks 911M shares today. KOSPI rips 5%.
TLDR
Moderna posted the biggest single-day biotech move in years on Wednesday. MRNA closed +176.97% at $183.01 and extended to +212% after-hours on a Phase 3 readout for the first ever mRNA treatment that prevents cancer rather than treats it. Over $50 billion in market cap was added in one session, and MRNA is now the second-best S&P 500 performer of 2026 at +491% year-to-date, behind only SanDisk. Overnight, Korea flipped from panic to euphoria. KOSPI ripped 5%, program buying was halted, and $185 billion was added back to Korean stocks after SK Hynix confirmed a $28.6 billion buyback. Alibaba missed on EPS by 25%. Tonight, SPCX unlocks 911 million more shares in its second tranche.
Market Regime
The tape has flipped from a leverage flush to a story-stock chase inside 24 hours. Wednesday closed with Moderna as the standout, biotech and AI-adjacent baskets both caught a bid. Overnight Korea reversed almost the entire Tue-Wed panic on a buyback management delivered exactly when the market needed it. Today’s setup is less about macro and more about three specific events: SPCX unlock, Alibaba open reaction, and any post-print drift in Moderna.
What could break it: SPCX slipping through $140 reverses the squeeze narrative and drags the pre-IPO trade with it. BABA breaking lower on the EPS miss signals the Wednesday panic in Asia was more information than Thursday’s bounce. MRNA giving back a large chunk of +212% before Friday’s scientific briefing cools the biotech chase before it starts.
Bullish Factors
- Moderna Phase 3 added $50 billion in market cap in one session, one of the largest single-day cap gains in biotech history. A working cancer prevention platform changes the multiple entirely.
- SK Hynix $28.6 billion buyback with permanent share cancellation worked in one session. KOSPI +5%, SKHY +10%, Samsung +6% today.
- Two of the S&P’s three biggest 2026 winners are now on retail radar. SNDK is #1 at +400% YTD, MRNA is #2 at +491% YTD. Different sectors, same AI-adjacency logic.
- Cathie Wood loading Cerebras into weakness, ARK bought 78,756 CBRS shares after last week’s -17.5% AH earnings drop.
- $185 billion added back to Korean stocks in one session after $650 billion was flushed on Wednesday. Real money returns fast once the leverage flush completes.
Bearish Factors
- SPCX second unlock today, 911 million more shares become tradable on a tape still fragile from Wednesday’s selloff. $147 and $140 are the two lines that matter.
- Alibaba EPS missed by 25%. Revenue barely beat, but the shortfall says margins are compressing. Read-across risk to JD, PDD, BIDU into their next prints.
- Asian retail is trading like a coin flip. KOSPI down 6.5% one session, up 5% the next. Foreign flows only return once volatility calms.
- MRNA +212% is priced for perfection. Commercialisation takes 12-24 months. Friday’s scientific briefing on cancer type and side effects is the risk.
- Chinese consumer tech margins shrinking while global chip demand stays strong. Two different stories in the same AI bucket, and the China leg is bleeding.
Asian Markets This Morning
KOSPI staged the exact mirror of Wednesday’s crash. The index rallied 5% and Korea Exchange halted program buying for five minutes at 11:57 local time, the flip side of Wednesday’s program-selling halt. SKHY added 10%, Samsung 6%, both tied directly to the $28.6 billion buyback confirmed on Wednesday evening. ₩261 trillion, roughly $185 billion, was added back to Korean market cap in one session, recovering almost the entire Tue-Wed drawdown. Nikkei and Hang Seng traded quieter, absorbing the read that when Asian management commits real capital, retail flows follow inside hours. Alibaba reported before the US open and the print was mixed, setting Chinese tech up for a soft New York open.
What Moved Wall Street Today
Wednesday’s session belonged to Moderna. MRNA closed +176.97% at $183.01 and extended to +212% after-hours on positive Phase 3 data for the first mRNA treatment ever to prevent cancer rather than treat it. Details on cancer type and mechanism come Friday. The move added over $50 billion in market cap in one day and lifted the biotech complex, with NVAX, BNTX and other mRNA-adjacent names catching a bid.
Outside the Moderna trade, tape action was thinner. SNDK held near $1,808 as the #1 S&P performer of 2026, though MRNA closing the YTD gap in a single session took momentum out of the trade. SPCX drifted into the second unlock at roughly $150. Historical note: Google went public 22 years ago today at a $23 billion valuation and is up 18,161% since, a frame for how big-year IPOs like SPCX, Anthropic, CXMT and Unitree can play out over a decade or two.
Assets in Focus
MRNA: $50 billion in one day
One of the largest single-day cap gains in biotech history. Post-print drift on a story of this size typically lasts 3-5 days. Friday’s scientific briefing on cancer type and mechanism is the next catalyst. Not on the CoinDCX Global Futures retail list yet, but the #2 S&P position and $50 billion day make it worth watching for platform coverage.
SPCX: Second unlock day
Approximately 911 million more shares tradable from today. The Aug 6 first tranche absorbed cleanly on a strong tape. Today’s lands on a more mixed tape but fundamentals are intact: Nvidia $21 billion holding, UBS $210 target, Elon 48.4%, and Monday’s $105 billion OpenAI Ohio backstop. SPCX added $119.6 billion in cap on Monday alone, part of which has already been given back.
BABA: Q1 FY27 EPS miss 25%
Revenue $39.96 billion narrowly beat the $39.9 billion bar. EPS $1.27 missed the $1.69 expectation by 25%. Revenue in-line means growth is happening, but the EPS shortfall says margins are compressing. Likely drivers: continued Cloud and AI infrastructure spend, plus core commerce pricing pressure from Pinduoduo and Douyin. Read-across into JD, PDD, BIDU. Positive tell would be BABA holding through the US open despite the miss.
SKHY: Buyback rescue confirmed
SK Hynix US ADR added 10%, Samsung Electronics 6%. Trigger: Wednesday’s confirmation of $28.6 billion in buybacks with permanent share cancellation, plus a 50% FCF shareholder return target through 2027. Textbook case for how capital return can rescue a broken tape. The KOSPI -6.5% flush from Wednesday has been almost fully reversed in one day. Watch for other Korean chip names to follow, Samsung has an even bigger cash pile.
SNDK: Still #1, but MRNA is closing the gap
SanDisk near $1,808, still the top S&P 500 performer of 2026. MRNA closing the YTD gap in one session takes short-term momentum out of the trade, but the memory-cycle thesis is intact. BofA Buy with $200-250 FY30 target on Micron as the read-across. If SNDK holds while MRNA gives back, the AI memory story is intact.
Index Levels to Watch
DRAM index: still tracking the memory-cycle beta trade. SKHY plus 10% and SNDK holding near $1,808 keep the index bid. Watch for a mean-reversion pull if MRNA continues to draw money away from AI hardware into biotech.
NSDQ100: first support near recent-week base, first resistance at prior week high. Moves this week have been squeeze-driven rather than trend-driven, so intraday reference more than overnight bias.
KOSPI: 6,600 is the level that held during Wednesday’s flush. 6,900 is the first resistance, 7,000 the psychological line, 7,200 was the pre-crash zone. If Friday holds above 6,750, the reversal is confirmed.
Disclaimer
This blog is for information and market context only. Nothing here is trading advice, a recommendation, or a solicitation to buy or sell any security or futures contract. Trading in leveraged products carries significant risk, including potential loss beyond your initial margin. Prices and levels referenced are as of publication and change constantly. Consult a SEBI-registered advisor before making investment decisions. CoinDCX Global Futures allows Indian traders to access US stock perpetuals in INR under FEMA-compliant frameworks.
Frequently Asked Questions
Q1. Why did Moderna stock jump 212%?
Moderna reported positive Phase 3 results on the first mRNA treatment ever to prevent cancer rather than treat it. The regular session closed +176.97% at $183.01, and after-hours extended to +212%. Over $50 billion in market cap was added in one day. Details on which cancer type and the mechanism will be released at a scientific briefing on Friday.
Q2. What is the SPCX unlock happening today?
SpaceX's second lockup tranche expires today, approximately 911 million additional shares become tradable. It is the second of a scheduled series of unlocks. The Aug 6 first unlock was absorbed cleanly because the tape was strong. Today's happens on a more mixed tape after this week's volatility. The levels that matter are $147 on the upside for a clean absorption and $140 on the downside as the squeeze-reversal line.
Q3. Why did the KOSPI rip 5% today?
Korea Exchange halted program buying for five minutes at 11:57 local time as $185 billion was added back to Korean stocks. The trigger was Wednesday's confirmation from SK Hynix of a $28.6 billion buyback with permanent share cancellation. SKHY added 10% on the day and Samsung 6%. The move is the exact mirror of Wednesday's -6.5% panic, when program selling was halted for the first time.
Q4. What did Alibaba report and why did EPS miss?
Alibaba reported Q1 FY27 revenue of $39.96 billion, a narrow beat of the $39.9 billion consensus. EPS came in at $1.27 versus $1.69 expected, a 25% miss. Revenue in-line means growth is still happening, but the EPS shortfall means margins are compressing. Likely drivers are continued AI and cloud investment, plus pricing pressure from Pinduoduo and Douyin in core commerce.
Q5. What is the CFTC Innovation Advisory Committee meeting?
The CFTC's Innovation Advisory Committee holds its inaugural meeting at 10:30 PM IST tonight. It is a scheduled event on the calendar and will be livestreamed on CFTC.gov. Formation of the committee is part of the regulator's build-out of expertise across newer market structures.
